Press Releases
Date picker
Category
Results per page
Kancera’s FRACTAL study results to be presented at the ESC 2024 Conference
Kancera AB (publ) announces that the results from the FRACTAL study will be presented at the European Society of Cardiology (ESC) annual conference on September 2, 2024.
Phase Ib completed and the recommended phase II dose is set in the ongoing KANDOVA study
Kancera AB (publ) today reports that the first part, phase Ib, has been successfully completed in the ongoing KANDOVA study, a combined phase Ib/IIa study of Kancera’s candidate drug KAND567…
Interim Report First Quarter 2024, January 1 – March 31 Kancera AB (publ.), org.no. 556806-8851
Regulatory
The period in brief – financial summary for the first quarter 2024Net sales amounted to SEK 0 million (SEK 0 million)R&D expenses amounted to SEK 11,4 million (SEK 15,2 million)Operating…
Kancera provides operational update regarding the KANDOVA study and reports increased patient recruitment
In connection with the upcoming Interim Report for the first quarter 2024, Kancera AB (publ) provides an operational update regarding KANDOVA, a combined phase Ib/IIa study of KAND567 in ovarian…
Kancera appoints new Chief Scientific Officer and extends management team
Kancera AB (publ) today announces that Robert Edfors is appointed as new Chief Scientific Officer and Senior Vice President Clinical Development and that the management team is extended with two…
Kancera meets the primary objectives of the KAND145 clinical phase I study
Kancera AB (publ) today reports positive results from the clinical phase I study with KAND145 in healthy subjects and that the primary objectives of the study were met:KAND145 is safe…
Kancera announces the outcome of the company’s rights issue
Regulatory
The board of directors of Kancera AB (”Kancera” or the ”Company”), hereby announces the outcome of the Company's rights issue of shares with preferential rights for the Company's existing shareholders…
Kancera publishes prospectus in connection with the company’s rights issue
Regulatory
Kancera AB (”Kancera” or the ”Company”) announced on February 23, 2024, that the board of directors has resolved to carry out a new issue of shares with preferential rights for…
Kancera resolves on a rights issue of approximately SEK 121.9 million
Regulatory
The board of directors of Kancera AB (”Kancera” or the ”Company”), has today, based on the issue authorization from the annual general meeting held on May 25, 2023, resolved on…
Interim Report Fourth Quarter 2023, October 1 – December 31 Kancera AB (publ.), org.no. 556806-8851
Regulatory
The period in brief – financial summary for the fourth quarterNet sales amounted to SEK 0 million (SEK 0).R&D expenses amounted to SEK 17,1 million (SEK 11,6 million).Operating income amounted…